HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Jubilant Pharmova Ltd Stock Comparison

Cohance Lifesciences Ltd vs Jubilant Pharmova Ltd Stock Comparison

Last Updated on: Jun 04, 2025

Key Highlights

  • The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 1020 as of 04 Jun 15:30.
  • The P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 yearsThe P/E Ratio of Jubilant Pharmova Ltd changed from 4.4 on March 2020 to 116.5 on March 2024 . This represents a CAGR of 92.56% over 5 years.
  • The Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 yearsThe Market Cap of Jubilant Pharmova Ltd changed from ₹ 3964 crore on March 2020 to ₹ 9056 crore on March 2024 . This represents a CAGR of 17.97% over 5 years.
  • The revenue of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79% The revenue of Jubilant Pharmova Ltd for the Mar '25 is ₹ 1940 crore as compare to the Dec '24 revenue of ₹ 1830 crore. This represent the growth of 6%.
  • The ebitda of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94% The ebitda of Jubilant Pharmova Ltd for the Mar '25 is ₹ 353.9 crore as compare to the Dec '24 ebitda of ₹ 277.4 crore. This represent the growth of 27.58%.
  • The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% The net profit of Jubilant Pharmova Ltd changed from ₹ 6 crore to ₹ 151.3 crore over 8 quarters. This represents a CAGR of 402.16% .
  • The Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Jubilant Pharmova Ltd changed from 24.8 % on March 2020 to 251.58 % on March 2024 . This represents a CAGR of 58.94% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Jubilant Pharmova Ltd

  • Jubilant Pharmova Limited was initially incorporated as 'Vam Organic Chemicals Limited' on June 21, 1978.
  • The Company name was thereafter changed to 'Jubliant Organosys Limited' in November, 2001 and to 'Jubilant Life Sciences Limited' in October, 2009 and the Company attained its new name 'Jubilant Pharmova Limited' in February, 2021. Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
  • The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
  • The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA.

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

Jubilant Pharmova Ltd News Hub

News

Board of Jubilant Pharmova recommends final dividend

Jubilant Pharmova announced that the Board of Directors of the Company at its meeting held...

Read more

16 May 2025 14:12

News

Jubilant Pharmova jumps after reporting turnaround Q4 performance

Revenue from operations increased 9.7% YoY to Rs 1,915.80 crore in Q4 FY25. The company re...

Read more

16 May 2025 16:07

News

Jubilant Pharmova to hold board meeting

Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 16 May 2...

Read more

02 May 2025 13:52

News

Jubilant Pharmova arm gets EIR from USFDA for Maryland facility

The US Food and Drug Administration (USFDA) had classified the inspection as voluntary act...

Read more

13 Mar 2025 10:18

News

Volumes spurt at Jubilant Pharmova Ltd counter

K E C International Ltd, Indian Bank, J B Chemicals & Pharmaceuticals Ltd, Birla Corporati...

Read more

13 Mar 2025 11:00

News

Jubilant Pharmova announces acquisition of 80% stake in JASMIN

Jubilant Biosys Innovative Research Services, Singapore (JBIRSPL), a subsidiary of Jubilan...

Read more

29 Jan 2025 09:03

SWOT Analysis Of Jubilant Pharmova Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Jubilant Pharmova Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Suven Pharmaceuticals Ltd and Jubilant Pharmova Ltd

Which company has a larger market capitalization, Suven Pharmaceuticals Ltd or Jubilant Pharmova Ltd?

Market cap of Suven Pharmaceuticals Ltd is 25,975 Cr while Market cap of Jubilant Pharmova Ltd is 18,449 Cr

What are the key factors driving the stock performance of Suven Pharmaceuticals Ltd and Jubilant Pharmova Ltd?

The stock performance of Suven Pharmaceuticals Ltd and Jubilant Pharmova Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Pharmaceuticals Ltd and Jubilant Pharmova Ltd?

As of June 4, 2025, the Suven Pharmaceuticals Ltd stock price is INR ₹1020.4. On the other hand, Jubilant Pharmova Ltd stock price is INR ₹1158.15.

How do dividend payouts of Suven Pharmaceuticals Ltd and Jubilant Pharmova Ltd compare?

To compare the dividend payouts of Suven Pharmaceuticals Ltd and Jubilant Pharmova Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions